You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.
Mergers and acquisitions in the omics space rose for the second year in a row, but the increase was significantly less than the 33 percent uptick in 2015 deals.
The company anticipates adjusted earnings per share of $3.85 to $3.95 for the full year.
The investment bank said Danaher's recent acquisitions of Cepheid and Phenomenex increase its potential for revenue growth.
Cepheid noted that the cartridge is not currently part of its five-year commercial plan, but the firm is in discussions with outside parties to push development forward.
Cepheid is now an indirect wholly owned subsidiary of Danaher, and the firm's stock will no longer be traded on the Nasdaq.
The GenomeWeb Index fell nearly 9 percent in October, doubling back on September's 5 percent gain and underperforming the Dow and the Nasdaq.
The company said it ultimately plans to use the liquidity from the credit facility to fund a portion of its pending $4 billion acquisition of Cepheid.
The $4 billion acquisition is now cleared in the US, Germany, Austria, and South Africa.
The company's revenues were in line with analyst expectations, while its adjusted earnings per share of $.87 beat expectations.
The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.
New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.
In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.
Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.